RT Journal Article
SR Electronic
T1 Comorbid chronic pain and depression: Shared risk factors and differential antidepressant effectiveness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.23.20110841
DO 10.1101/2020.05.23.20110841
A1 Roughan, William H.
A1 Campos, Adrián I.
A1 García-Marín, Luis M.
A1 Cuéllar-Partida, Gabriel
A1 Lupton, Michelle K.
A1 Hickie, Ian B.
A1 Medland, Sarah E.
A1 Wray, Naomi R.
A1 Byrne, Enda M.
A1 Ngo, Trung Thanh
A1 Martin, Nicholas G.
A1 Rentería, Miguel E.
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2020.05.23.20110841.abstract
AB The bidirectional relationship between depression and chronic pain is well recognized, but their clinical management remains challenging. Here we characterize the shared risk factors and outcomes for their comorbidity in the Australian Genetics of Depression cohort study (N=13,839). Participants completed online questionnaires about chronic pain, psychiatric symptoms, comorbidities, treatment response and general health. Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors. Cumulative linked logistic regressions assessed the effect of chronic pain on treatment response for ten different antidepressants. Chronic pain was associated with an increased risk of depression (OR=1.86 [1.37–2.54]), recent suicide attempt (OR=1.88[1.14–3.09]), higher use of tobacco (OR=1.05 [1.02–1.09]) and misuse of painkillers (e.g., opioids; OR=1.31 [1.06–1.62]). Participants with comorbid chronic pain and depression reported fewer functional benefits from antidepressant use and lower benefits from sertraline (OR=0.75[0.68–0.83]), escitalopram (OR=0.75[0.67–0.85]) and venlafaxine (OR=0.78[0.68–0.88]) when compared to participants without chronic pain. Furthermore, participants taking sertraline (OR=0.45[0.30–0.67]), escitalopram (OR=0.45[0.27–0.74]) and citalopram (OR=0.32[0.15–0.67]) specifically for chronic pain (among other indications) reported lower benefits compared to other participants taking these same medications but not for chronic pain. These findings reveal novel insights into the complex relationship between chronic pain and depression. Treatment response analyses indicate differential effectiveness between particular antidepressants and poorer functional outcomes for these comorbid conditions. Further examination is warranted in targeted interventional clinical trials, which also include neuroimaging genetics and pharmacogenomics protocols. This work will advance the delineation of disease risk indicators and novel aetiological pathways for therapeutic intervention in comorbid pain and depression as well as other psychiatric comorbidities.Competing Interest StatementIBH has been: Commissioner of Australia's National Mental Health Commission (2012-2018); Co-director of Health and Policy at the Brain and Mind Centre, University of Sydney; leading community-based and pharmaceutical industry-supported projects (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) focused on the identification and better management of anxiety and depression; a member of the Medical Advisory Panel for Medibank Private until October 2017; a board member of Psychosis Australia Trust; a member of the Veterans Mental Health Clinical Reference group; and Chief Scientific Advisor to and an equity shareholder in Innowell.Funding StatementData collection for the Australian Genetics of Depression Study was possible thanks to funding from the Australian National Health and Medical Research Council (NHMRC) to NGM (GNT1086683); data collection for the Prospective Imaging Study of Ageing: Genes, Brain and Behaviour was possible thanks to an NHMRC Dementia Research Team Grant administered by QIMR Berghofer Medical Research Institute (GNT1095227). The research funders did not participate in the study design, data analyses, results interpretation or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study comprised data from two cohorts: the Australian Genetics of Depression Study (AGDS) and the Prospective Imaging Study of Aging (PISA). Participants in both groups provided informed consent before participating. These studies, including all questionnaires used, were approved by the QIMR Berghofer Medical Research Institute's Human Research Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode used as part of this study is available from the authors upon reasonable request. Participant data is protected and confidential.